Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to comprehend and willing to sign an informed consent form.~2. Male and female subjects between 30 and 83 years old, inclusive.~3. Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria for at least 3 years.~4. Disease severity Stages I-III (modified Hoehn \&Yahr staging) at ON.~5. Treated with L-DOPA/DDCI for at least 1 year with clear clinical improvement.~6. Treated with 3 to 8 daily doses of L-DOPA/DDCI, which can include a slow-release formulation.~7. On a stable regimen of L-DOPA/DDCI and other anti-PD drugs for at least 4 weeks before screening.~8. Signs of wearing-off phenomenon (end-of-dose deterioration) for a minimum of 4 weeks before screening with average total daily OFF time while awake of at least 1.5 hours, excluding the early morning pre-first dose OFF, despite optimal anti-PD therapy (based on the investigator's judgment.~Exclusion Criteria:~1. Non-idiopathic PD (atypical parkinsonism, secondary \[acquired or symptomatic\] parkinsonism, Parkinson-plus syndrome).~2. Dyskinesia disability score \>3 in the Unified Parkinson's Disease Rating Scale UPDRS) Sub-section IV A, item 33.~3. Severe and/or unpredictable OFF periods.~4. Treatment with prohibited medication: entacapone, tolcapone, neuroleptics, venlafaxine, MAO inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1mg/day), or antiemetics with antidopaminergic action (except domperidone) within the month before screening.~5. Treatment with apomorphine within the month before screening or likely to be needed at any time during the study.~6. Dosage change of concomitant anti-PD medication within 4 weeks of screening.~7. Previous or planned (during the entire study duration, including the OL period)deep brain stimulation.~8. Previous stereotactic surgery (e.g. pallidotomy, thalamotomy) for PD or with planned stereotactic surgery during the study period.~9. Any investigational medicinal product within the 3 months (or within 5 half-lives, whichever is longer) before screening.~10. Any medical condition that might place the subject at increased risk or interfere with assessments.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 83 Years
- Healthy Volunteers: f

Study Arms:
- BIA 9-1067 25 mg once daily (QD). (Type: EXPERIMENTAL): BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).
- BIA 9-1067 50 mg once daily (QD). (Type: EXPERIMENTAL): BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).
- Placebo (Type: PLACEBO_COMPARATOR): PLC, Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).